---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-035859"
form_type: "8-K"
ticker: "ROIV"
cik: "0001635088"
company_name: "Roivant Sciences Ltd."
filed_at: "2026-09-08T13:15:54+00:00"
generated_at: "2026-09-08T13:17:12.855414+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Roivant's mosliciguat hits all PHocus endpoints: PVR -56.3%, 6MWD +35.2m in PH-ILD

## Summary
- PHocus Phase 2 met primary endpoint: placebo-adjusted PVR reduction -56.3% (p<0.0001) at Week 16 in PH-ILD
- Secondary endpoints met: 6MWD +35.2m (p=0.0027), NT-proBNP -53.2% (p=0.0002) at Week 16
- Week 24 exploratory: 6MWD +52.7m, NT-proBNP -75.9% (both nominal p<0.0001)
- Cough lower than placebo (12.1% vs 18.2%); favorable safety profile
- Phase 3 PHrontier initiated (~375 patients); results presented at ERS 2026

## SEC filing metadata
- accession: 0001140361-26-035859
- form_type: 8-K
- ticker: ROIV
- cik: 0001635088
- company_name: Roivant Sciences Ltd.
- filed_at: 2026-09-08T13:15:54+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1635088/000114036126035859/0001140361-26-035859-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1635088/000114036126035859/ef20081686_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-035859
- JSON: https://secwatch.observer/filing/0001140361-26-035859.json
- Plain text: https://secwatch.observer/filing/0001140361-26-035859.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.